Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.40 per share
-
Shares outstanding
-
23.6M
-
Number of holders
-
67
-
Total 13F shares, excl. options
-
109M
-
Shares change
-
+5.03M
-
Total reported value, excl. options
-
$260M
-
Value change
-
+$12.4M
-
Put/Call ratio
-
0.06
-
Number of buys
-
30
-
Number of sells
-
-24
-
Price
-
$2.38
Significant Holders of Autolus Therapeutics plc - Ordinary Shares, par value NIS 0.40 per share (AUTL) as of Q2 2023
79 filings reported holding AUTL - Autolus Therapeutics plc - Ordinary Shares, par value NIS 0.40 per share as of Q2 2023.
Autolus Therapeutics plc - Ordinary Shares, par value NIS 0.40 per share (AUTL) has 67 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 109M shares
.
Largest 10 shareholders include Syncona Portfolio Ltd (21.3M shares), Blackstone Inc. (20.5M shares), Deep Track Capital, LP (15M shares), TFG Asset Management GP Ltd (12M shares), Paradigm Biocapital Advisors LP (9.22M shares), ARMISTICE CAPITAL, LLC (7.26M shares), Nantahala Capital Management, LLC (4.27M shares), Frazier Life Sciences Management, L.P. (3.75M shares), Perpetual Ltd (2M shares), and SCHRODER INVESTMENT MANAGEMENT GROUP (1.67M shares).
This table shows the top 67 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.